Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. More Details
Excellent balance sheet with solid track record.
Share Price & News
How has Bio-Rad Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BIO's weekly volatility (4%) has been stable over the past year.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: BIO underperformed the US Life Sciences industry which returned 45.7% over the past year.
Return vs Market: BIO underperformed the US Market which returned 50.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Bio-Rad Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs It Time To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
3 months ago | Simply Wall StIs It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
4 months ago | Simply Wall StDon't Ignore The Fact That This Insider Just Sold Some Shares In Bio-Rad Laboratories, Inc. (NYSE:BIO)
Is Bio-Rad Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BIO ($589.74) is trading above our estimate of fair value ($406.66)
Significantly Below Fair Value: BIO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BIO is good value based on its PE Ratio (4.3x) compared to the US Life Sciences industry average (44.4x).
PE vs Market: BIO is good value based on its PE Ratio (4.3x) compared to the US market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: BIO's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: BIO is good value based on its PB Ratio (1.7x) compared to the US Life Sciences industry average (6.8x).
How is Bio-Rad Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIO's earnings are forecast to decline over the next 3 years (-44.3% per year).
Earnings vs Market: BIO's earnings are forecast to decline over the next 3 years (-44.3% per year).
High Growth Earnings: BIO's earnings are forecast to decline over the next 3 years.
Revenue vs Market: BIO's revenue (3.6% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: BIO's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIO's Return on Equity is forecast to be low in 3 years time (4.4%).
How has Bio-Rad Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIO has a high level of non-cash earnings.
Growing Profit Margin: BIO's current net profit margins are higher than last year (67.8%).
Past Earnings Growth Analysis
Earnings Trend: BIO's earnings have grown significantly by 65.4% per year over the past 5 years.
Accelerating Growth: BIO's earnings growth over the past year (159.5%) exceeds its 5-year average (65.4% per year).
Earnings vs Industry: BIO earnings growth over the past year (159.5%) exceeded the Life Sciences industry 19.5%.
Return on Equity
High ROE: BIO's Return on Equity (38.6%) is considered high.
How is Bio-Rad Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: BIO's short term assets ($2.2B) exceed its short term liabilities ($609.9M).
Long Term Liabilities: BIO's short term assets ($2.2B) do not cover its long term liabilities ($2.7B).
Debt to Equity History and Analysis
Debt Level: BIO's debt to equity ratio (0.01%) is considered satisfactory.
Reducing Debt: BIO's debt to equity ratio has reduced from 16.6% to 0.01% over the past 5 years.
Debt Coverage: BIO's debt is well covered by operating cash flow (50535.1%).
Interest Coverage: BIO earns more interest than it pays, so coverage of interest payments is not a concern.
What is Bio-Rad Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Norman Schwartz (70 yo)
Mr. Norman D. Schwartz has been the Chief Executive Officer and President of Bio-Rad Laboratories, Inc. since January 1, 2003 and has been its Chairman since 2012. Mr. Schwartz served as Vice President of ...
CEO Compensation Analysis
Compensation vs Market: Norman's total compensation ($USD7.99M) is about average for companies of similar size in the US market ($USD11.20M).
Compensation vs Earnings: Norman's compensation has been consistent with company performance over the past year.
Experienced Management: BIO's management team is considered experienced (2.9 years average tenure).
Experienced Board: BIO's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BIO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bio-Rad Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Bio-Rad Laboratories, Inc.
- Ticker: BIO
- Exchange: NYSE
- Founded: 1952
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$18.038b
- Shares outstanding: 29.76m
- Website: https://www.bio-rad.com
Number of Employees
- Bio-Rad Laboratories, Inc.
- 1000 Alfred Nobel Drive
- United States
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers produ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/17 23:02|
|End of Day Share Price||2021/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.